HTML Microdata document

This HTML5 document contains 428 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
dc	http://purl.org/dc/elements/1.1/
n8	http://pubannotation.org/docs/sourcedb/PMC/sourceid/
n3	http://purl.jp/bio/10/colil/id/
rdfs	http://www.w3.org/2000/01/rdf-schema#
bibo	http://purl.org/ontology/bibo/
n2	http://purl.jp/bio/10/colil/ontology/201303#
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n9	http://www.ncbi.nlm.nih.gov/pmc/articles/
n7	http://togows.dbcls.jp/entry/pubmed/
n11	http://dx.doi.org/
xsdh	http://www.w3.org/2001/XMLSchema#
n5	http://purl.org/spar/doco/

Statements

Subject Item: n3:29552200
rdf:type: n2:RelevantPaper n2:ReferencePaper n2:CitationPaper
rdfs:seeAlso: n7:29552200 n8:0 n9:0 n11:10.3892%2Fol.2018.8051
bibo:cites: n3:25335738 n3:11263866 n3:25120740 n3:11846609 n3:27225749 n3:26621583 n3:27253518 n3:27573351 n3:25025570 n3:24913707 n3:25751671 n3:28055103 n3:21192816 n3:10487552 n3:25169522 n3:24091605 n3:27889771 n3:28782726 n3:21279958 n3:27351322 n3:21124918 n3:22226625 n3:9111868 n3:26356590 n3:26855592 n3:20127360 n3:25954275
n2:cocitationWith: n3:24607403 n3:28397828 n3:25888636 n3:29845398 n3:30733805 n3:27411517 n3:24504189 n3:8464707 n3:20074520 n3:27330410 n3:27225749 n3:23196196 n3:21284870 n3:17051156 n3:27267855 n3:26840024 n3:25909162 n3:18371393 n3:17122772 n3:27507615 n3:27045981 n3:30207593 n3:27611934 n3:27611935 n3:31593802 n3:28985214 n3:28819374 n3:27611937 n3:27499099 n3:18049477 n3:26797015 n3:24921913 n3:29681949 n3:27889771 n3:26783961 n3:19805294 n3:25979842 n3:29506506 n3:22895640 n3:10694938 n3:7140811 n3:24618343 n3:29970499 n3:30692202 n3:28070170 n3:27200096 n3:28403901 n3:30303590 n3:27931044 n3:28123556
n2:hasRelevantBibliographicResourceOf: _:vb645206152 _:vb645206153 _:vb645206154 _:vb645206155 _:vb645206156 _:vb645206157 _:vb645206158 _:vb645206159 _:vb645206168 _:vb645206169 _:vb645206170 _:vb645206171 _:vb645206172 _:vb645206173 _:vb645206174 _:vb645206175 _:vb645206160 _:vb645206161 _:vb645206162 _:vb645206163 _:vb645206164 _:vb645206165 _:vb645206166 _:vb645206167 _:vb645206184 _:vb645206185 _:vb645206186 _:vb645206187 _:vb645206188 _:vb645206189 _:vb645206190 _:vb645206191 _:vb645206176 _:vb645206177 _:vb645206178 _:vb645206179 _:vb645206180 _:vb645206181 _:vb645206182 _:vb645206183 _:vb645206200 _:vb645206201 _:vb645206192 _:vb645206193 _:vb645206194 _:vb645206195 _:vb645206196 _:vb645206197 _:vb645206198 _:vb645206199
n2:pmcid: PMC0
bibo:doi: 10.3892%2Fol.2018.8051
n5:contains: _:vb75310224 _:vb75310219 _:vb75310222 _:vb75310203

Subject Item: _:vb75310203
rdf:type: n5:Section
dc:title: introduction
n5:contains: _:vb75310204 _:vb75310205 _:vb75310206 _:vb75310207 _:vb75310216 _:vb75310217 _:vb75310218 _:vb75310208 _:vb75310209 _:vb75310210 _:vb75310211 _:vb75310212 _:vb75310213 _:vb75310214 _:vb75310215

Subject Item: _:vb75310204
rdf:type: n2:Context
rdf:value: At present, lung cancer is the leading cause of cancer-associated mortality worldwide in men and women (>>1<<). Despite the discovery and application of new standard therapies, the current 5-year relative survival rate for lung cancer remains at 18% (1).
n2:mentions: n3:28055103

Subject Item: _:vb75310205
rdf:type: n2:Context
rdf:value: Despite the discovery and application of new standard therapies, the current 5-year relative survival rate for lung cancer remains at 18% (>>1<<). Lung cancer is classified into two major categories according to pathological type: Non-small cell lung cancer (NSCLC) and small cell carcinoma. NSCLC, the most common type of lung cancer, accounts for ~80–85% of all lung cancer cases
n2:mentions: n3:28055103

Subject Item: _:vb75310206
rdf:type: n2:Context
rdf:value: NSCLC, the most common type of lung cancer, accounts for ~80–85% of all lung cancer cases (>>2<<). The disease stage at diagnosis, including the T stage, has been reported to predict the prognosis of NSCLC (3). However, the effects of gene expression on tumor growth in NSCLC remain far from being completely understood.
n2:mentions: n3:10487552

Subject Item: _:vb75310207
rdf:type: n2:Context
rdf:value: The disease stage at diagnosis, including the T stage, has been reported to predict the prognosis of NSCLC (>>3<<). However, the effects of gene expression on tumor growth in NSCLC remain far from being completely understood.
n2:mentions: n3:22226625

Subject Item: _:vb75310208
rdf:type: n2:Context
rdf:value: CD44, a 85–90 kDa transmembrane glycoprotein, is widely expressed on the surface of cells in the majority of normal and carcinomatous human tissues (>>4<<). In normal human cells, CD44 has been reported to be involved in multitudinous cellular functions, including proliferation, adhesion, migration, hematopoiesis, lymphocyte activation, homing and extravasation (5).
n2:mentions: n3:25025570

Subject Item: _:vb75310209
rdf:type: n2:Context
rdf:value: In normal human cells, CD44 has been reported to be involved in multitudinous cellular functions, including proliferation, adhesion, migration, hematopoiesis, lymphocyte activation, homing and extravasation (>>5<<). In various types of human malignancy, high levels of CD44 expression have been demonstrated to be associated with cancer progression (6–10). In lung cancer, diverse studies have clarified that the expression of CD44 is associated with
n2:mentions: n3:9111868

Subject Item: _:vb75310210
rdf:type: n2:Context
rdf:value: In various types of human malignancy, high levels of CD44 expression have been demonstrated to be associated with cancer progression (>>6<<–10). In lung cancer, diverse studies have clarified that the expression of CD44 is associated with tumorigenesis and malignant features of NSCLC (11,12). Tumor and serum expression of CD44 have been confirmed as prognostic indicators for
n2:mentions: n3:27889771 n3:27253518 n3:27351322 n3:25751671 n3:26855592

Subject Item: _:vb75310211
rdf:type: n2:Context
rdf:value: In lung cancer, diverse studies have clarified that the expression of CD44 is associated with tumorigenesis and malignant features of NSCLC (>>11<<,12). Tumor and serum expression of CD44 have been confirmed as prognostic indicators for patients with NSCLC (13,14). In addition, overexpression of CD44 is associated with the occurrence and migration of NSCLC (15). Furthermore,
n2:mentions: n3:24913707

Subject Item: _:vb75310212
rdf:type: n2:Context
rdf:value: In lung cancer, diverse studies have clarified that the expression of CD44 is associated with tumorigenesis and malignant features of NSCLC (11,>>12<<). Tumor and serum expression of CD44 have been confirmed as prognostic indicators for patients with NSCLC (13,14). In addition, overexpression of CD44 is associated with the occurrence and migration of NSCLC (15). Furthermore,
n2:mentions: n3:25169522

Subject Item: _:vb75310213
rdf:type: n2:Context
rdf:value: Tumor and serum expression of CD44 have been confirmed as prognostic indicators for patients with NSCLC (>>13<<,14). In addition, overexpression of CD44 is associated with the occurrence and migration of NSCLC (15). Furthermore, accumulating evidence has demonstrated that lung cancer cells expressing CD44 tend to have stem cell-like properties
n2:mentions: n3:20127360

Subject Item: _:vb75310214
rdf:type: n2:Context
rdf:value: Tumor and serum expression of CD44 have been confirmed as prognostic indicators for patients with NSCLC (13,>>14<<). In addition, overexpression of CD44 is associated with the occurrence and migration of NSCLC (15). Furthermore, accumulating evidence has demonstrated that lung cancer cells expressing CD44 tend to have stem cell-like properties (16–18)
n2:mentions: n3:27225749

Subject Item: _:vb75310215
rdf:type: n2:Context
rdf:value: In addition, overexpression of CD44 is associated with the occurrence and migration of NSCLC (>>15<<). Furthermore, accumulating evidence has demonstrated that lung cancer cells expressing CD44 tend to have stem cell-like properties (16–18) and that cancer stem cells are responsible for driving metastasis (16). CD44 also contributes to
n2:mentions: n3:27573351

Subject Item: _:vb75310216
rdf:type: n2:Context
rdf:value: Furthermore, accumulating evidence has demonstrated that lung cancer cells expressing CD44 tend to have stem cell-like properties (>>16<<–18) and that cancer stem cells are responsible for driving metastasis (16).
n2:mentions: n3:21124918 n3:26621583 n3:25335738

Subject Item: _:vb75310217
rdf:type: n2:Context
rdf:value: Furthermore, accumulating evidence has demonstrated that lung cancer cells expressing CD44 tend to have stem cell-like properties (16–18) and that cancer stem cells are responsible for driving metastasis (>>16<<). CD44 also contributes to drug resistance in lung cancer (19). Although evidence demonstrating that CD44 may act as an oncogene in NSCLC exists, direct cell experiments are still required to further confirm the effect of CD44 on the
n2:mentions: n3:26621583

Subject Item: _:vb75310218
rdf:type: n2:Context
rdf:value: CD44 also contributes to drug resistance in lung cancer (>>19<<). Although evidence demonstrating that CD44 may act as an oncogene in NSCLC exists, direct cell experiments are still required to further confirm the effect of CD44 on the malignant phenotype of lung cancer cells.
n2:mentions: n3:24091605

Subject Item: _:vb75310219
rdf:type: n5:Section
dc:title: materials and methods
n5:contains: _:vb75310220 _:vb75310221

Subject Item: _:vb75310220
rdf:type: n2:Context
rdf:value: Sections were routinely stained, as described in our previous study (>>20<<). Briefly, the sections were immersed in xylene to remove the paraffin, washed in a graded series of ethanol, immersed in citrate buffer and then incubated in a high-pressure sterilization oven for antigen retrieval with citrate buffer at
n2:mentions: n3:21192816

Subject Item: _:vb75310221
rdf:type: n2:Context
rdf:value: The relative gene expression levels were calculated by the 2−ΔΔCq method (where ΔCq=Cqtarget- Cqcontrol) (>>21<<).
n2:mentions: n3:11846609

Subject Item: _:vb75310222
rdf:type: n5:Section
dc:title: results
n5:contains: _:vb75310223

Subject Item: _:vb75310223
rdf:type: n2:Context
rdf:value: There was no significant difference between CD44 expression and age, sex, smoking status, pathology type, N classification or TNM stage (>>22<<). However, the level of CD44 expression was positively associated with an advanced T classification (P<0.05; Table I). A total of 58.9% of cases (33 of 56) stained positive for CD44 in the T1 group, while 80.0% of cases (28 of 35) stained
n2:mentions: n3:28782726

Subject Item: _:vb75310224
rdf:type: n5:Section
dc:title: discussion
n5:contains: _:vb75310228 _:vb75310229 _:vb75310230 _:vb75310231 _:vb75310225 _:vb75310226 _:vb75310227 _:vb75310236 _:vb75310237 _:vb75310232 _:vb75310233 _:vb75310234 _:vb75310235

Subject Item: _:vb75310225
rdf:type: n2:Context
rdf:value: In previous studies, high expression of CD44 was hypothesized to be associated with poor prognosis in NSCLC (>>14<<,23). High expression of CD44 was also reported to be associated with not only occurrence and migration (15) but also metastasis (24) and drug resistance (19) of NSCLC.
n2:mentions: n3:27225749

Subject Item: _:vb75310226
rdf:type: n2:Context
rdf:value: In previous studies, high expression of CD44 was hypothesized to be associated with poor prognosis in NSCLC (14,>>23<<). High expression of CD44 was also reported to be associated with not only occurrence and migration (15) but also metastasis (24) and drug resistance (19) of NSCLC.
n2:mentions: n3:25120740

Subject Item: _:vb75310227
rdf:type: n2:Context
rdf:value: High expression of CD44 was also reported to be associated with not only occurrence and migration (>>15<<) but also metastasis (24) and drug resistance (19) of NSCLC.
n2:mentions: n3:27573351

Subject Item: _:vb75310228
rdf:type: n2:Context
rdf:value: High expression of CD44 was also reported to be associated with not only occurrence and migration (15) but also metastasis (>>24<<) and drug resistance (19) of NSCLC.
n2:mentions: n3:26356590

Subject Item: _:vb75310229
rdf:type: n2:Context
rdf:value: High expression of CD44 was also reported to be associated with not only occurrence and migration (15) but also metastasis (24) and drug resistance (>>19<<) of NSCLC.
n2:mentions: n3:24091605

Subject Item: _:vb75310230
rdf:type: n2:Context
rdf:value: In the present study, an association between a higher CD44-positive expression rate and higher T stage was observed in NSCLC, which was consistent with the report from Shinohara et al (>>14<<) where significant associations were observed between CD44 expression and clinicopathological factors including T stage, N stage, pathological stage and histological type following immunohistochemical analysis of a cohort consisting of
n2:mentions: n3:27225749

Subject Item: _:vb75310231
rdf:type: n2:Context
rdf:value: were observed between CD44 expression and clinicopathological factors including T stage, N stage, pathological stage and histological type following immunohistochemical analysis of a cohort consisting of 261 consecutive patients (>>12<<), but the present study failed to identify a significant association between CD44 expression and occurrence or metastasis.
n2:mentions: n3:25169522

Subject Item: _:vb75310232
rdf:type: n2:Context
rdf:value: There are also certain reports indicating that CD44 variant 6 (CD44v6) is associated with disease progression in NSCLC (>>13<<,25,26). Luo et al (23) reported that high expression of CD44v6 was associated with histopathological type and lymph node metastasis by using meta-analysis for a total of 921 patients with NSCLC from ten studies. However, whether the
n2:mentions: n3:20127360

Subject Item: _:vb75310233
rdf:type: n2:Context
rdf:value: There are also certain reports indicating that CD44 variant 6 (CD44v6) is associated with disease progression in NSCLC (13,>>25<<,26). Luo et al (23) reported that high expression of CD44v6 was associated with histopathological type and lymph node metastasis by using meta-analysis for a total of 921 patients with NSCLC from ten studies. However, whether the
n2:mentions: n3:11263866

Subject Item: _:vb75310234
rdf:type: n2:Context
rdf:value: There are also certain reports indicating that CD44 variant 6 (CD44v6) is associated with disease progression in NSCLC (13,25,>>26<<). Luo et al (23) reported that high expression of CD44v6 was associated with histopathological type and lymph node metastasis by using meta-analysis for a total of 921 patients with NSCLC from ten studies. However, whether the expression
n2:mentions: n3:21279958

Subject Item: _:vb75310235
rdf:type: n2:Context
rdf:value: Luo et al (>>23<<) reported that high expression of CD44v6 was associated with histopathological type and lymph node metastasis by using meta-analysis for a total of 921 patients with NSCLC from ten studies.
n2:mentions: n3:25120740

Subject Item: _:vb75310236
rdf:type: n2:Context
rdf:value: These results were constant with those of a previous report, where purified CD44-positive cells were demonstrated to have higher tumorigenicity than negative cells in vitro and in vivo (>>17<<). With increasing research focusing on the function of CD44 in cancer, it is generally accepted that CD44 is a prime therapeutic target for cancer interventions (27). The present study supports the hypothesis that CD44 is a potential
n2:mentions: n3:21124918

Subject Item: _:vb75310237
rdf:type: n2:Context
rdf:value: With increasing research focusing on the function of CD44 in cancer, it is generally accepted that CD44 is a prime therapeutic target for cancer interventions (>>27<<). The present study supports the hypothesis that CD44 is a potential therapeutic target for NSCLC. Inhibition of CD44 expression, either by siRNAs or by CRISPR/Cas9 gene editing targeting NSCLC, may suppress lung cancer cell proliferation
n2:mentions: n3:25954275

Subject Item: _:vb645206152
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:19805294

Subject Item: _:vb645206153
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 4
n2:hasRelevantPaperId: n3:29681949

Subject Item: _:vb645206154
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:24618343

Subject Item: _:vb645206155
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:28403901

Subject Item: _:vb645206156
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 3
n2:hasRelevantPaperId: n3:25979842

Subject Item: _:vb645206157
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27411517

Subject Item: _:vb645206158
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:30207593

Subject Item: _:vb645206159
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25909162

Subject Item: _:vb645206160
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27267855

Subject Item: _:vb645206161
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28397828

Subject Item: _:vb645206162
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:30303590

Subject Item: _:vb645206163
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:30692202

Subject Item: _:vb645206164
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27330410

Subject Item: _:vb645206165
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27507615

Subject Item: _:vb645206166
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:18371393

Subject Item: _:vb645206167
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27200096

Subject Item: _:vb645206168
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:8464707

Subject Item: _:vb645206169
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27045981

Subject Item: _:vb645206170
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27931044

Subject Item: _:vb645206171
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:29506506

Subject Item: _:vb645206172
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17051156

Subject Item: _:vb645206173
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:21284870

Subject Item: _:vb645206174
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:23196196

Subject Item: _:vb645206175
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:29845398

Subject Item: _:vb645206176
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27889771

Subject Item: _:vb645206177
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28819374

Subject Item: _:vb645206178
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26783961

Subject Item: _:vb645206179
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:18049477

Subject Item: _:vb645206180
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24921913

Subject Item: _:vb645206181
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26840024

Subject Item: _:vb645206182
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28985214

Subject Item: _:vb645206183
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27225749

Subject Item: _:vb645206184
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:20074520

Subject Item: _:vb645206185
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:29970499

Subject Item: _:vb645206186
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:17122772

Subject Item: _:vb645206187
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24607403

Subject Item: _:vb645206188
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27611934

Subject Item: _:vb645206189
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27499099

Subject Item: _:vb645206190
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:10694938

Subject Item: _:vb645206191
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28070170

Subject Item: _:vb645206192
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:25888636

Subject Item: _:vb645206193
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27611935

Subject Item: _:vb645206194
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:28123556

Subject Item: _:vb645206195
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:30733805

Subject Item: _:vb645206196
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:7140811

Subject Item: _:vb645206197
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:24504189

Subject Item: _:vb645206198
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:31593802

Subject Item: _:vb645206199
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:27611937

Subject Item: _:vb645206200
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:22895640

Subject Item: _:vb645206201
rdf:type: n2:RelevantBibliographicResource
n2:RelevantScore: 2
n2:hasRelevantPaperId: n3:26797015